Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltanexor in High-Risk Primary HMA-Refractory MDS (China Part F)
CTR20221453Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltanexor in myelodysplastic syndrome (MDS), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall response rate (ORR). Started Jun 2022; status: terminated.
02
Drugs
eltanexor
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20221453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221453.